Healthy volunteers help unlock secrets of new HIV drug
NCT ID NCT07066722
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study looked at how a new HIV drug, VH4524184, is absorbed by the body and how it interacts with other common medicines. It involved 126 healthy adults aged 18 to 60. The goal was to gather information, not to treat HIV, so participants did not have HIV. Results will help guide future dosing and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Lenexa, Kansas, 66219, United States
-
GSK Investigational Site
Salt Lake City, Utah, 84124, United States
Conditions
Explore the condition pages connected to this study.